Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

26.40 -1.60 (-5.70%)
Streaming Delayed Price Updated: 1:33 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Joseph Hand as General Counsel and EVP of Operations
Via Investor Brand Network
Exposures Product Safety
TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Prepares for Potential Fibromyalgia Drug Approval, Reports Q1 Results
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data for TNX-1700 at AACR 2025
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Showcases Single-Dose Mpox Vaccine Data at World Vaccine Congress
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Collaborates With Makana Therapeutics on Xenotransplantation Research
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Data on Fibromyalgia Drug at AAPM 2025
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at 2025 Jones Trading Healthcare Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches TONIX ONE™ Digital Platform to Transform Migraine Care
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Non-Opioid Fibromyalgia Drug Toward FDA Decision
Via Investor Brand Network
Exposures Product Safety
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
Via ACCESS Newswire
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.
Via ACCESS Newswire
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at AAPM 2025 PainConnect Meeting
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Fibromyalgia Drug Without Advisory Committee Review
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Single-Dose Vaccine for Mpox
Via Investor Brand Network
Exposures Product Safety
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
Via ACCESS Newswire
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4, Full-Year 2024 Financial Results, Highlights Key Developments
Via Investor Brand Network
Exposures Product Safety
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 BIO-Europe Spring Convention
Via Investor Brand Network
Exposures Product Safety
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances TNX-1500 to Address Organ Transplant Rejection
Via Investor Brand Network
Exposures Product Safety
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
Via ACCESS Newswire
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at Zacks SCR Life Sciences Virtual Forum
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures MCDC Grant for TNX-801 Smallpox and Mpox Vaccine Development
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 Virtual Investor Summit
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data on TNX-102 SL for Fibromyalgia
Via Investor Brand Network
Topics Emissions
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Preliminary 2024 Financial Results
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Positive Phase 1 Results for TNX-1500 in Transplant and Autoimmune Therapy
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at BIO CEO & Investor Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Siobhan Fogarty to Chief Technical Officer
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces 1-for-100 Reverse Stock Split
Via Investor Brand Network
Exposures Product Safety
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.